CX3CR1 antibody - HS-516 003

CX3CR1 is a receptor for the C-X3-C chemokine fractalkine
Rabbit polyclonal purified antibody
Cat. No.: HS-516 003
Amount: 50 µg
Price: $370.00
Cat. No. HS-516 003 50 µg specific antibody, lyophilized. Affinity purified with the immunogen. Albumin and azide were added for stabilization. For reconstitution add 50 µl H2O to get a 1mg/ml solution in PBS. Then aliquot and store at -20°C to -80°C until use.
Antibodies should be stored at +4°C when still lyophilized. Do not freeze!
Applications
 
WB: 1 : 500 up to 1 : 1000 (AP-staining) (see remarks) gallery  
IP: not tested yet
ICC: 1 : 500 gallery  
IHC: 1 : 500 (see remarks) gallery  
IHC-P: 1 : 750 gallery  
Immunogen Synthetic peptide corresponding to residues near the carboxy terminus of mouse CX3CR1 (UniProt Id: Q9Z0D9)
Reactivity Reacts with: mouse (Q9Z0D9).
Weaker signal: rat (P35411).
No signal: human (P49238).
Other species not tested yet.
Remarks

WB: Non-boiled samples are recommended when running SDS-PAGE.
IHC: Heat-mediated antigen retrieval (citrate buffer pH 6) is recommended for immunohistochemical staining.

Data sheet hs-516_003.pdf
Cat. No.: HS-516 003
Amount: 50 µg
Price: $370.00

Staining of the brain of a CX3CR1-EGFP transgene mouse with rabbit anti-CX3CR1 (red) and guinea pig anti-GFP (green).

Background

CX3CR1 is a member of the seven-transmembrane G-protein coupled receptor (GPCR) family. Its ligand CX3CL1, also known as fractalkine or neurotactin, is expressed by neurons, dendritic cells and inflamed endothelial cells, among others.
CX3CR1 is expressed by several cell types, including monocytes, macrophages and microglia in the brain, dendritic cells, natural killer (NK) cells and some T lymphocytes. This receptor is crucial for regulating cell adhesion and migration, and plays an important role in immune response and inflammation. Recent literature highlights the importance of the receptor in several diseases, including cardiovascular disorders (1), neurodegenerative diseases e.g. influencing the progression of Alzheimer's disease (2), liver fibrosis (3) and cancer (4). It is a promising therapeutic target not only in cancer but also in chronic kidney disease (5).

Protocols for HS-516 003